AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11669586 — intervention group
Group type: COMPARATOR
Intervention: USS examination by radiologists in Group 2 (n=231)
Number of subjects: 302
Study 9415946 — intervention group
Group type: COMPARATOR
Intervention: Normal sleep schedule (2300‐0700 hours)
Number of subjects: 3
Study 9415946 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial sleep deprivation (0400‐0800 hours)
Number of subjects: 3
Study 9415946 — intervention group
Group type: EXPERIMENTAL
Intervention: Total sleep deprivation
Number of subjects: 3
Study 8073358 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic dissection
Number of subjects: 0
Study 3129806 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium preparations (lithium carbonate, lithium oxybutyrate)
Number of subjects: 201
Study 3129806 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 201
Study 3129806 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 201
Study 3129806 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 201
Study 3129806 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 201
Study 3129806 — intervention group
Group type: COMPARATOR
Intervention: Placebo and standard antiulcerative therapy
Number of subjects: 201
Study 30079775 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Self-Efficacy Enhancing Program (DSEEP)
Number of subjects: 113
Study 30079775 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 113
Study 29126966 — intervention group
Group type: EXPERIMENTAL
Intervention: Densovirus infection
Number of subjects: 0
Study 29126966 — intervention group
Group type: EXPERIMENTAL
Intervention: High IG plant (Plantago lanceolata)
Number of subjects: 0
Study 29126966 — intervention group
Group type: COMPARATOR
Intervention: Low IG plant (P. major)
Number of subjects: 0
Study 29126966 — intervention group
Group type: COMPARATOR
Intervention: Surface sterilization to exclude microbes
Number of subjects: 0
Study 28819835 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin
Number of subjects: 2681
Study 26576944 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 mmol/kg gadobutrol
Number of subjects: 30
Study 26576944 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.10 mmol/kg gadobutrol
Number of subjects: 30
Study 26576944 — intervention group
Group type: COMPARATOR
Intervention: 0.20 mmol/kg Gd‐DTPA
Number of subjects: 30
Study 23207186 — intervention group
Group type: EXPERIMENTAL
Intervention: YGD (3 tablets)
Number of subjects: 58
Study 23207186 — intervention group
Group type: EXPERIMENTAL
Intervention: SFF (5g in 100ml water)
Number of subjects: 58
Study 23207186 — intervention group
Group type: EXPERIMENTAL
Intervention: YGD + SFF
Number of subjects: 58
Study 23207186 — intervention group
Group type: COMPARATOR
Intervention: Placebo (water and placebo)
Number of subjects: 58
Study 21545667 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring and feedback plus counseling (TMC)
Number of subjects: 252
Study 21545667 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring and feedback (TM)
Number of subjects: 252
Study 21545667 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 252
Study 18629524 — intervention group
Group type: EXPERIMENTAL
Intervention: FREMS therapy
Number of subjects: 35
Study 18629524 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 35
Study 16582130 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 800 mcg vaginally on study day 1, with a repeat dose if indicated on day 3.
Number of subjects: 485
Study 12755982 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic sulodexide
Number of subjects: 30
Study 12755982 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic prednisone
Number of subjects: 30
Study 12755982 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 30
Study 10617948 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine
Number of subjects: 12
Study 10617948 — intervention group
Group type: EXPERIMENTAL
Intervention: Dealcoholized red wine
Number of subjects: 12
Study 10617948 — intervention group
Group type: COMPARATOR
Intervention: Phenol-stripped red wine
Number of subjects: 12
Study 10617948 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 12
Study 10617948 — intervention group
Group type: EXPERIMENTAL
Intervention: All beverages
Number of subjects: 12
Study 8858462 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg i.v. at 8 hourly intervals (group 1 and 2)
Number of subjects: 42
Study 8858462 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg i.v. at 12 hourly intervals (group 3)
Number of subjects: 42
Study 8858462 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg i.v. at 12 hourly intervals (group 4)
Number of subjects: 42
Study 1512337 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (4 days of therapy)
Number of subjects: 45
Study 1512337 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 6437183 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopamidol
Number of subjects: 27
Study 6437183 — intervention group
Group type: COMPARATOR
Intervention: Methylglucamine iothalamate (Conray-60)
Number of subjects: 27
Study 30328569 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenzhu Guanxin Recipe Granules (SGR) 10 g/day for 12 weeks
Number of subjects: 184
Study 30328569 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184
Study 30328569 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenzhu Guanxin Recipe Granules (SGR)
Number of subjects: 184
Study 30024973 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension-Type Headache presenteeism
Number of subjects: 78
Study 27583882 — intervention group
Group type: EXPERIMENTAL
Intervention: Collateral Meridian Therapy (CMT)
Number of subjects: 70
Study 27583882 — intervention group
Group type: COMPARATOR
Intervention: Local Tender Area Related Meridians (LTARM)
Number of subjects: 70
Study 24889137 — intervention group
Group type: EXPERIMENTAL
Intervention: Powdered black tea solids (3 cups per day)
Number of subjects: 111
Study 24889137 — intervention group
Group type: COMPARATOR
Intervention: Flavonoid-free flavour- and caffeine-matched placebo
Number of subjects: 111
Study 22863159 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination aliskiren/hydrochlorothiazide (HCT) 150/12.5 mg
Number of subjects: 0
Study 22863159 — intervention group
Group type: COMPARATOR
Intervention: Aliskiren 150 mg (force-titrated to 300/25 mg and 300 mg)
Number of subjects: 0
Study 20582746 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/kg 0.2% ropivacaine
Number of subjects: 45
Study 20582746 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg ketamine
Number of subjects: 45
Study 20582746 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/kg 0.2% ropivacaine plus 0.5 mg/kg ketamine
Number of subjects: 45
Study 20582746 — intervention group
Group type: COMPARATOR
Intervention: Group R (ropivacaine)
Number of subjects: 45
Study 20582746 — intervention group
Group type: EXPERIMENTAL
Intervention: Group K (ketamine)
Number of subjects: 45
Study 20582746 — intervention group
Group type: EXPERIMENTAL
Intervention: Group R+K (ropivacaine plus ketamine)
Number of subjects: 45
Study 20582746 — intervention group
Group type: EXPERIMENTAL
Intervention: Group R+K
Number of subjects: 45
Study 18765450 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol plus ibuprofen
Number of subjects: 0
Study 18765450 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol
Number of subjects: 0
Study 18765450 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 0
Study 15914990 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate-based dentifrice
Number of subjects: 10
Study 15914990 — intervention group
Group type: EXPERIMENTAL
Intervention: Silica-based dentifrice
Number of subjects: 10
Study 15914990 — intervention group
Group type: COMPARATOR
Intervention: Negative control
Number of subjects: 10
Study 12908893 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet (HSAFA)
Number of subjects: 25
Study 12908893 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet (LSAFA)
Number of subjects: 25
Study 12908893 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet rich in unsaturated fatty acids (HUFA)
Number of subjects: 25
Study 9813398 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin 200 mg t.i.d.
Number of subjects: 72
Study 9813398 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin (all doses)
Number of subjects: 72
Study 9053413 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal eye drop preparation
Number of subjects: 0
Study 9053413 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 0
Study 2550646 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (ACE inhibitor)
Number of subjects: 0
Study 2550646 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 972960 — intervention group
Group type: EXPERIMENTAL
Intervention: Monetary reward for successful performance
Number of subjects: 0
Study 972960 — intervention group
Group type: COMPARATOR
Intervention: No supplementary incentive
Number of subjects: 0
Study 30301233 — intervention group
Group type: EXPERIMENTAL
Intervention: Moringa + CEN
Number of subjects: 360
Study 30301233 — intervention group
Group type: EXPERIMENTAL
Intervention: Cricket + CEN
Number of subjects: 360
Study 30301233 — intervention group
Group type: COMPARATOR
Intervention: CEN alone
Number of subjects: 360
Study 28034999 — intervention group
Group type: EXPERIMENTAL
Intervention: Free snus for ad libitum use
Number of subjects: 543
Study 26121788 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rehydration therapy (ORT) group, allowed to drink clear liquids until 2 hours before anesthesia induction
Number of subjects: 58
Study 26121788 — intervention group
Group type: COMPARATOR
Intervention: Control group, fasted from 21:00 the night before surgery
Number of subjects: 58
Study 23241727 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 µg of misoprostol orally 12 hours before the procedure
Number of subjects: 0
Study 23241727 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21939942 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin monotherapy
Number of subjects: 554
Study 21939942 — intervention group
Group type: COMPARATOR
Intervention: Heparin plus glycoprotein IIb/IIIa inhibitor (GPI)
Number of subjects: 554
Study 21939942 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 554
Study 21939942 — intervention group
Group type: COMPARATOR
Intervention: Drug-eluting stents (DES)
Number of subjects: 554
Study 18652102 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (3 ml of isobaric bupivacaine 5 mg/ml)
Number of subjects: 120
Study 18652102 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine (3 ml of isobaric ropivacaine 5 mg/ml)
Number of subjects: 120
Study 18652102 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine (3 ml of isobaric levobupivacaine 5 mg/ml)
Number of subjects: 120
Study 18652102 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 120
Study 16710757 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine sulphate
Number of subjects: 32
Study 16710757 — intervention group
Group type: COMPARATOR
Intervention: Control (n=14)
Number of subjects: 32
Study 12599027 — intervention group
Group type: EXPERIMENTAL
Intervention: Open drainage system (secretion goes directly into the bandage)
Number of subjects: 0
Study 12599027 — intervention group
Group type: EXPERIMENTAL
Intervention: Gravity drainage systems
Number of subjects: 0
Study 12599027 — intervention group
Group type: EXPERIMENTAL
Intervention: High-vacuum suction drainage
Number of subjects: 0
Study 12599027 — intervention group
Group type: EXPERIMENTAL
Intervention: Redon drainage
Number of subjects: 0
Study 12599027 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic drainage insertion in uncomplicated thyroid surgery and hernia repair
Number of subjects: 0
Study 12599027 — intervention group
Group type: EXPERIMENTAL
Intervention: Drainage insertion for up to 72 hours
Number of subjects: 0
Study 12599027 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine microbiological examination of the tip of the drainage tube
Number of subjects: 0
Study 11163674 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard titre measles vaccine given at age 9 months
Number of subjects: 0
Study 11163674 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard titre measles vaccine given at age 6 months
Number of subjects: 0
Study 11163674 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccine groups
Number of subjects: 0
Study 9644284 — intervention group
Group type: EXPERIMENTAL
Intervention: Long foreperiod schedule
Number of subjects: 6
Study 9644284 — intervention group
Group type: EXPERIMENTAL
Intervention: Short foreperiod schedule
Number of subjects: 6
Study 9644284 — intervention group
Group type: EXPERIMENTAL
Intervention: Memorized condition (MM)
Number of subjects: 6
Study 9644284 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonmemorized condition (NM)
Number of subjects: 6
Study 9644284 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall foreperiod effect
Number of subjects: 6
Study 7820191 — intervention group
Group type: EXPERIMENTAL
Intervention: Medrogestone (M) at a dose of 10 mg/day from D4 to D24
Number of subjects: 10
Study 7820191 — intervention group
Group type: COMPARATOR
Intervention: Control (Cycle 1)
Number of subjects: 10
Study 2830642 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (cisplatin 70 mg/m2 i.v. day one, etoposide 100 mg/m2 i.v. day one, 200 mg/m2 orally days 2 and 3, repeated every third week to a maximum of 4 cycles)
Number of subjects: 234
Study 2830642 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (42 Gy given in 15 fractions over a 3-week period)
Number of subjects: 234
Study 1385603 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron (4 mg)
Number of subjects: 9
Study 1385603 — intervention group
Group type: EXPERIMENTAL
Intervention: amphetamine (15 mg)
Number of subjects: 9
Study 1385603 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 9
Study 1385603 — intervention group
Group type: COMPARATOR
Intervention: placebo/amphetamine (15 mg)
Number of subjects: 9
Study 836481 — intervention group
Group type: EXPERIMENTAL
Intervention: Remotivation-Activities sequence
Number of subjects: 32
Study 836481 — intervention group
Group type: EXPERIMENTAL
Intervention: Remotivation-only sequence
Number of subjects: 32
Study 836481 — intervention group
Group type: COMPARATOR
Intervention: Remotivation-Social Living sequence
Number of subjects: 32
Study 836481 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study 30239152 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional counseling intervention
Number of subjects: 106
Study 30239152 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 106
Study 28954882 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 200 mg BID for 6-18 months
Number of subjects: 121
Study 28954882 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules for 6-18 months
Number of subjects: 121
Study 28954882 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 200 mg BID
Number of subjects: 121
Study 23660738 — intervention group
Group type: EXPERIMENTAL
Intervention: PDT delivered twice within 1 week (group A)
Number of subjects: 28
Study 23660738 — intervention group
Group type: EXPERIMENTAL
Intervention: PDT delivered only once (group B)
Number of subjects: 28
Study 23660738 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment without activating the laser (group C)
Number of subjects: 28
Study 23660738 — intervention group
Group type: EXPERIMENTAL
Intervention: PDT (both groups A and B)
Number of subjects: 28
Study 23962145 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade 1 [123I]FP-CIT SPECT scan
Number of subjects: 83
Study 23962145 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade 2 [123I]FP-CIT SPECT scan
Number of subjects: 83
Study 23962145 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade 3 [123I]FP-CIT SPECT scan
Number of subjects: 83
Study 23962145 — intervention group
Group type: COMPARATOR
Intervention: Dopamine transporter uptake ratios
Number of subjects: 83
Study 22545106 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.7 g of DHA and 0.6 g EPA daily for 6 months
Number of subjects: 174
Study 22545106 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 174
Study 19182454 — intervention group
Group type: EXPERIMENTAL
Intervention: Detrusitol
Number of subjects: 69
Study 19182454 — intervention group
Group type: COMPARATOR
Intervention: Oxybutynin
Number of subjects: 69
Study 19182454 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 17404558 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal intermittent positive pressure ventilation
Number of subjects: 88
Study 17404558 — intervention group
Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure
Number of subjects: 88
Study 15194015 — intervention group
Group type: EXPERIMENTAL
Intervention: Pl(A2) allele in smokers
Number of subjects: 592
Study 15194015 — intervention group
Group type: COMPARATOR
Intervention: Pl(A2) allele
Number of subjects: 592
Study 12108813 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisystemic Therapy (MST)
Number of subjects: 80
Study 12108813 — intervention group
Group type: COMPARATOR
Intervention: Usual Community Services (Control)
Number of subjects: 80
Study 9675649 — intervention group
Group type: EXPERIMENTAL
Intervention: Helicobacter pylori-positive group
Number of subjects: 37
Study 9675649 — intervention group
Group type: COMPARATOR
Intervention: Helicobacter pylori-negative group
Number of subjects: 37
Study 7995008 — intervention group
Group type: COMPARATOR
Intervention: Quinidine monotherapy
Number of subjects: 10
Study 7995008 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment of amiloride (1 mumol/L) and quinidine (10 mumol/L)
Number of subjects: 10
Study 7995008 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment of amiloride and quinidine
Number of subjects: 10
Study 2574728 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine once daily
Number of subjects: 171
Study 2574728 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine twice daily
Number of subjects: 171
Study 2574728 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine and Nifedipine combined with a beta-blocker
Number of subjects: 171
Study 2574728 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 171
Study 4892037 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrazepam (Mogadon)
Number of subjects: 27
Study 4892037 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrazepam
Number of subjects: 27
Study 4892037 — intervention group
Group type: COMPARATOR
Intervention: Butobarbitone
Number of subjects: 27
Study 31108553 — intervention group
Group type: EXPERIMENTAL
Intervention: Planning competence training (PKT)
Number of subjects: 467
Study 31108553 — intervention group
Group type: COMPARATOR
Intervention: Control groups (KG-B, KG-C, KG-D)
Number of subjects: 467
Study 30689903 — intervention group
Group type: EXPERIMENTAL
Intervention: RYGB surgery after a 4-week low-calorie diet
Number of subjects: 19
Study 30689903 — intervention group
Group type: COMPARATOR
Intervention: Standard medical treatment (control group)
Number of subjects: 19
Study 28739538 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended PE training (4-day workshop plus expert case consultation)
Number of subjects: 180
Study 28739538 — intervention group
Group type: COMPARATOR
Intervention: Standard PE training (4-day workshop only)
Number of subjects: 180
Study 28739538 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended PE training
Number of subjects: 180
Study 28739538 — intervention group
Group type: COMPARATOR
Intervention: Standard PE training
Number of subjects: 180
Study 25440652 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous superior vena cava clamped drainage
Number of subjects: 0
Study 25440652 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous superior vena cava unclamped drainage
Number of subjects: 0
Study 22623063 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamstrings plus Cocker‐Arnold procedure (group B)
Number of subjects: 60
Study 22623063 — intervention group
Group type: COMPARATOR
Intervention: Hamstrings (control group A)
Number of subjects: 60
Study 22256771 — intervention group
Group type: EXPERIMENTAL
Intervention: Shuxuetong injection
Number of subjects: 80
Study 22256771 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment (Control)
Number of subjects: 80
Study 19826110 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus cisplatin and etoposide
Number of subjects: 63
Study 16169159 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) techniques integrated into the initial contact and evaluation session
Number of subjects: 423
Study 16169159 — intervention group
Group type: COMPARATOR
Intervention: Standard intake/evaluation session
Number of subjects: 423
Study 16169159 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) techniques
Number of subjects: 423
Study 16169159 — intervention group
Group type: COMPARATOR
Intervention: Standard intervention
Number of subjects: 423
Study 15467219 — intervention group
Group type: COMPARATOR
Intervention: Sho-hange-ka-bukuryo-to
Number of subjects: 0
Study 15467219 — intervention group
Group type: COMPARATOR
Intervention: Nichin-to
Number of subjects: 0
Study 15467219 — intervention group
Group type: COMPARATOR
Intervention: Zingiberis Rhizoma
Number of subjects: 0
Study 15467219 — intervention group
Group type: COMPARATOR
Intervention: Pinelliae Tuber
Number of subjects: 0
Study 10792124 — intervention group
Group type: EXPERIMENTAL
Intervention: 10- to 14-day therapies
Number of subjects: 13
Study 10792124 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-day therapies
Number of subjects: 13
Study 10792124 — intervention group
Group type: COMPARATOR
Intervention: 7-day therapies
Number of subjects: 13
Study 10792124 — intervention group
Group type: COMPARATOR
Intervention: 10-day therapies
Number of subjects: 13
Study 9213839 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 80